4.3 Review

The inflammatory cytokines: molecular biomarkers for major depressive disorder?

Journal

BIOMARKERS IN MEDICINE
Volume 9, Issue 2, Pages 169-180

Publisher

FUTURE MEDICINE LTD
DOI: 10.2217/BMM.14.29

Keywords

antidepressants; biomarkers; cytokines; genetic; major depressive disorder; proteomic; transcriptomic

Ask authors/readers for more resources

Cytokines are pleotropic cell signaling proteins that, in addition to their role as inflammatory mediators, also affect neurotransmitter systems, brain functionality and mood. Here we explore the potential utility of cytokine biomarkers for major depressive disorder. Specifically, we explore how genetic, transcriptomic and proteomic information relating to the cytokines might act as biomarkers, aiding clinical diagnosis and treatment selection processes. We advise future studies to investigate whether cytokine biomarkers might differentiate major depressive disorder patients from other patient groups with overlapping clinical characteristics. Furthermore, we invite future pharmacogenetic studies to investigate whether early antidepressant-induced changes to cytokine mRNA or protein levels precede behavioral changes and act as longer-term predictors of clinical antidepressant response.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available